Newsletters and more news updates

The latest newsletter (Summer ’18) can be downloaded here. Just follow the link or right click the link and save as…

David Casley, Prospect Publicity 07860 369064; Email  prospect.bristol@gmail.com

MORE NEWS

Abiraterone ‘success’

One of the largest clinical trials for prostate cancer has given “powerful results”, say UK researchers. Abiraterone, when used for treating prostate cancer that has spread, was found to save lives when offered earlier (June ’17). See and here.

Cancer ‘killer’ claimed

A vaccine that could eliminate all traces of cancer has been revealed by US scientists. But it has been tried only on mice so far. See

Some treatment ‘unnecessary’

Thousands of men with prostate cancer get risky treatment they don’t need. New approaches could curb that, it’s claimed (Nov ’17). See

Isotope could be game-changer

A new brachytherapy isotope, Cesium-131, could be a game-changer, a US study indicates (Aug ’17). See

Remarkable results claimed for nuclear medicine treatment

Remarkable results are claimed for an experimental treatment in Australia for advanced prostate cancer patients who had exhausted all their options. It is a disruptive technology in the field of nuclear medicine, pioneered in Germany (Aug ’17). See

New hope for advanced patients

Scientists have developed a blood test that could pick out which men with advanced prostate cancer would benefit from a new drug treatment. The test detects cancer DNA, helping doctors check if precision drugs are working. Cancer Research UK said the test could “greatly improve survival”, but added that larger studies are needed to confirm if it is reliable. (Jun ’17). See

New treatment to be tried out

After a pilot study, an associate Australian professor is to lead a trial of 200 patients with nuclear medicine treatment – what he believes could be a game-changer in the treatment of advanced prostate cancer (July ’17). See

Ignorance over newer tests

Half of urologists are unaware of newer, more sensitive biomarker tests for detecting prostate cancer, according to a worldwide survey of 300 mainly European specialists. The new tests reduce the need for biopsies (July ’17). See

Defeating therapy resistance

A new US study sheds light on a signalling circuit in cells that drives therapy resistance in prostate cancer. Targeting the components of this circuit suppresses advanced cancer development. See.

Laser treatment success

Surgeons described a new treatment for early stage prostate cancer as “truly transformative”. The approach, tested in Europe, uses lasers and a drug made from deep-sea bacteria to kill tumours, without severe side effects. See.

Testosterone finding

Drastically altering the levels of testosterone could cause cancer cells to die even after they become hormone-resistant, according to research (Dec ’16). See.

Treatment breakthrough

After a bombardment of evidence from Prostate Cancer UK, NICE announced in November ’16 they will undertake an exceptional review of this cancer’s clinical guidelines. It will mean lifesaving new diagnosis and treatment sooner than expected. See.

PSA test row

PSA tests may be unnecessary, the Academy of Medical Royal Colleges reported (Oct ’16). But Prostate Cancer UK says thy are still the best first step until a more robust one suitable for a screening programme is devised. Several Prospect members wrote to the BBC or their MP about the situation. See. And crowdfunding donations were successfully sought for a new non-invasive and affordable diagnostic test for the early detection of this cancer. See.

World first hailed

Scientists in Belfast claim a major breakthrough in prostate cancer treatment. It is hoped the new discovery, hailed a world first, could help stop the spread of the disease and prevent relapses. Researchers have found that combining hormone therapy with a new drug, OCT1002, can improve treatment effectiveness. See.

Drug targets tumours

A radioactive drug, which behaves like the substance used to kill Russian ex-spy Alexander Litvinenko, could be used to treat prostate cancer patients. It targets tumours that have spread to the bones and has been approved by NICE. See.

Early detection claimed

Scientists at Israel’s Weizmann Institute might have found a prostate cancer cure, at least if it’s caught early. See.

Urine test created

Scientists have created a urine test for prostate cancer after trials on 155 men in Bristol. See

New diagnosis tool; Zytiga affordable

A new risk assessment tool for GPs is set to revolutionise prostate cancer diagnosis. See. And NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers. See.

More accurate predictions?

Patients might be offered a more accurate prediction of their prostate cancer risk with a novel method developed by Cambridge University researchers. See

Biopsies may be ‘out’

Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits are officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who don’t have a clinically significant prostate cancer. See. Latest on this here. And US researchers have identified a marker of aggressive prostate cancer. See

Tumour mapped and zapped

In a world first, Australian researchers have mapped the entire genome of a prostate tumour (Apr ’17). See. And an emerging treatment that involves zapping a prostate tumour briefly with more electricity than a bolt of lightning has been reported in Australia. Urologists in three countries are trialling the technology (Oct ’18). See

Improved PSA test in view

Birmingham researchers are working on an improved PSA test. See. And in April 2016 Tackle reached agreement on the best way to use the PSA test. The guidance, developed with and for GPs and practice nurses, is on better use of the test in men without symptoms. See

Cancer ‘breakthrough’

A new treatment which trains the immune system to attack “liquid” blood cancers has shown “extraordinary” results and could be a potential breakthrough in curing the disease. It is hoped to progress to patients with solid tumours, but this will be challenging and some of those treated suffered severe side effects. See